AstraZeneca CEO discusses impressive earnings, global expansion, innovative drugs, and pricing strategies. Shares surge, marking a significant jump since 2020. Is AstraZeneca stock a prime buy now? In-depth stock analysis reveals the company's robust fundamentals, despite a 7% YTD decline. Discover why $AZN remains a top investment pick.